BMI and Fatty Liver Disease

By Longevity Lab · Published: August 23, 2026

Based on peer-reviewed research — full source list at the end of this article. This is educational information, not medical advice.

Fatty liver disease tracks visceral and liver fat far more closely than it tracks BMI, which is why 10–20% of people with it have a body mass index under 25. It is the most common liver condition worldwide, it is usually silent, and the index that would normally prompt investigation frequently fails to. The compensating news is that it responds to weight loss more predictably than almost any other obesity-related condition: 7–10% of body weight resolves the inflammatory form in most people who reach it.

What the condition is

NAFLD — non-alcoholic fatty liver disease — increasingly reclassified as metabolic dysfunction-associated steatotic liver disease — is fat accumulation in more than 5% of liver cells in the absence of significant alcohol intake. It exists on a spectrum: simple Steatohepatosis (fatty liver) first, then steatohepatitis where inflammation and cell injury appear, then fibrosis, and in a minority cirrhosis.

Most people never progress past the first stage. The reason the condition matters is the size of the denominator: it affects roughly a quarter to a third of adults globally, so even a small progression rate produces a large number of cases.

The driver is not fat in general but fat in the wrong place. When subcutaneous storage capacity is exceeded, or when insulin resistance impairs it, lipid is deposited ectopically — in liver, muscle and around organs. That is why Visceral fat and liver fat rise together, and why total body weight is a poor guide to either.

Why lean people get it

Lean fatty liver is not a rare curiosity. It is more common in South and East Asian populations, in people with a genetic predisposition — the PNPLA3 I148M variant is the best-characterized — and in people with normal weight but poor body composition.

The metabolic profile is usually recognizable even when the BMI is not: raised triglycerides, low HDL, raised waist for height, sometimes raised fasting glucose. In other words, the same picture as normal-weight obesity, which is essentially what it is when seen from the liver.

Outcomes in lean fatty liver are not benign. Several cohort analyses find comparable or even higher all-cause mortality than in fatty liver with obesity, possibly because it is diagnosed later.

Screening without a scan

Ultrasound is the usual first imaging test, but two validated indices detect steatosis from measurements most people already have.

Fatty Liver Index combines BMI, waist circumference, triglycerides and GGT into a 0–100 score. Below 30 makes steatosis unlikely; above 60 makes it likely. Fatty Liver Index (FLI) computes it directly.

Hepatic Steatosis Index uses ALT, AST, BMI, sex and diabetes status — useful when you have liver enzymes but no GGT or triglycerides. Hepatic Steatosis Index (HSI) scores it, with 30.0 and 36.0 as the standard bounds.

Both include BMI as an input, which is exactly the right use of it: as one term among several rather than as the whole assessment. That is also why they detect cases the index alone would miss — a normal BMI with a large waist and raised triglycerides still scores.

The normal-ALT trap

A normal alanine aminotransferase does not rule out fatty liver. A substantial share of people with biopsy-confirmed disease, including some with steatohepatitis, have ALT inside the reference range.

Part of the problem is that the reference range itself is generous — it was derived from populations that included many undiagnosed cases. Several hepatology groups argue for lower upper limits, around 30 U/L in men and 19–25 U/L in women, rather than the 40–50 many labs report.

So an ALT of 35 with a waist over half your height is not reassurance. It is a reason to compute one of the indices above.

How much weight loss reverses it

This is where the evidence is unusually clear and unusually encouraging. In a prospective study of 293 patients with biopsy-proven steatohepatitis followed through a twelve-month lifestyle intervention:

Fibrosis regression is the striking finding. Scarring was long assumed to be one-directional, and this showed it is not, at least in the earlier stages.

Beyond weight itself, three things have specific evidence: reducing fructose and alcohol, adding aerobic exercise — which lowers liver fat even without weight loss — and a Mediterranean dietary pattern, which reduces hepatic fat independently of calories in several trials.

Frequently asked questions

Sources

Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.